QRxPharma Pty Ltd. Announces a $35 Million Capital Raising to Progress MoxDuo Formulations and Support Commercialisation of MoxDuo(R) IR
Published: Jul 25, 2011
The issue price under the Placement and Rights Issue is A$1.45 per share which represents a 10% discount to the last closing price of QRxPharma shares on 19 July 2011.
RBS Morgans Corporate Limited and Bell Potter Securities Limited were Joint Lead Managers to the Capital Raising.
QRxPharma intends to use the proceeds from the Placement and Rights Issue to progress MoxDuo® IR through FDA approval and commercialisation leading to product launch expected in 2012, to progress the development of MoxDuo controlled release (CR) and to provide additional working capital. The capital raising also puts the Company in a strong financial position as it negotiates with potential partners.
As announced to ASX on Monday 18 July 2011, the Company achieved another significant milestone as it commenced filing its New Drug Application (NDA) with the United States Food and Drug Administration (FDA) for MoxDuo IR for the treatment of moderate to severe acute pain, a $2.5 billion segment of the $8 billion spent annually on prescription opioids in the U.S. QRxPharma's product pipeline also includes intravenous (IV) and CR formulations which are in earlier stages of clinical development.
QRxPharma CEO and Managing Director, Dr. John Holaday commented, "We continue to make significant progress towards commercialising MoxDuo IR, having just initiated our NDA filing with the FDA. With this capital raising, we are in an excellent position to further develop our portfolio of Dual Opioid ® pain products as we await FDA feedback on our NDA over the coming year. These additional resources also place us in a solid position as we continue our partnering negotiations."
Dr. Peter Farrell, Chairman of QRxPharma, stated, "This capital raising will allow QRxPharma to further important milestones including the commercialisation of MoxDuo IR for acute pain management, as well as enabling significant progress with its MoxDuo CR formulation for chronic pain, which the Board believes will support partnering discussions and add significant shareholder value."
The Rights Issue is non-renounceable giving all eligible QRxPharma shareholders the opportunity to subscribe for 1 new QRxPharma share for every 20 existing QRxPharma shares held on the Record Date (7.00 p.m., 2 August 2011) at the issue price of A$1.45 per New Share. This is the same price paid by investors in the Placement. Participants in the Placement will also be eligible to participate in the Rights Issue. The Rights Issue is not underwritten.
Eligible shareholders will be able to apply for additional new shares at the same issue price being A$1.45 per share. (1)
New shares issued under the Rights Issue, and the Placement, will rank equally with existing ordinary shares on issue.
Post the Placement and Rights Issue (if fully subscribed), QRxPharma's net cash position (after expenses of the capital raising) will be A$41 million.
Further details regarding the timetable for the Rights Issue are included in the Annexure to this announcement.
QRxPharma Limited (ASX: QRX and OTCQX: QRXPY) is a clinical-stage specialty pharmaceutical company focused on the development and commercialisation of new treatments for pain management and central nervous system (CNS) disorders. Based on a development strategy that focuses on enhancing and expanding the clinical utility of currently marketed compounds, the Company's product portfolio includes both late and early stage clinical drug candidates with the potential for reduced risk, abbreviated development paths, and improved patient outcomes. The Company intends to co-promote its products in the U.S. and seeks strategic partnerships for worldwide markets. QRxPharma's lead product candidate, immediate release MoxDuo, successfully completed pivotal Phase 3 studies and the Company has filed its New Drug Application (NDA) with the US Food and Drug Administration (FDA). The Company's clinical pipeline includes an intravenous (IV) and continuous release (CR) formulation of MoxDuo, as well as other technologies in the fields of pain management, neurodegenerative disease and venomics. For more information, visit www.qrxpharma.com.
Forward Looking Statements
This release contains forward-looking statements. Forward-looking statements are statements that are not historical facts; they include statements about our beliefs and expectations. Any statement in this release that states our intentions, beliefs, expectations or predictions (and the assumptions underlying them) is a forward-looking statement. These statements are based on plans, estimates and projections as they are currently available to the management of QRxPharma. Forward-looking statements therefore speak only as of the date they are made, and we undertake no obligation to update publicly any of them in light of new information or future events. By their very nature, forward-looking statements involve risks and uncertainties. A number of important factors could therefore cause actual results to differ materially from those contained in any forward-looking statement. Such factors include risks relating to the stage of products under development; uncertainties relating to clinical trials; dependence on third parties; future capital needs; and risks relating to the commercialisation of the Company's proposed products.
Rights Issue Timetable
Friday 22 July 2011
708AA cleansing notice, offer document, and Appendix 3B lodged with the ASX
Friday 22 July 2011
Tuesday 26 July 2011
7.00 p.m., Tuesday 2 August 2011
Rights Issue opening date Rights Issue Booklet mailed to shareholders
Monday 8 August, 2011
5.00 p.m., Monday 22 August 2011
ASX notified of under-subscriptions
Thursday 25 August 2011
Tuesday 30 August 2011
Normal trading commences
Wednesday 31 August 2011
Dates and times are indicative only and subject to change without notice. All times and dates refer to AEST time (Sydney time).
1. Additional shares will be subject to availability. Applications for additional shares may be scaled at the sole discretion of QRxPharma Limited and the Joint Lead Managers.
SOURCE QRxPharma Limited